Should you buy Sagimet Biosciences Inc. Series A stock now?
Yes, the technical signal for Sagimet Biosciences Inc. Series A is currently BUY. Sagimet Biosciences Inc. Series A trades at $8.73 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.148 with rising momentum (signal: 0.056); RSI is at 67.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $26.20 points to 200.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Sagimet Biosciences Inc. Series A stock?
The average analyst price target for Sagimet Biosciences Inc. Series A is $26.20. The current price is $8.73, which gives an upside of 200.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $23.58 and $28.82.
Is Sagimet Biosciences Inc. Series A a dividend stock?
No, Sagimet Biosciences Inc. Series A does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Sagimet Biosciences Inc. Series A stock?
Sagimet Biosciences Inc. Series A is rated as a stock with extreme risk. the annual standard deviation is 86.7%, which classifies the stock as extreme risk.
Is Sagimet Biosciences Inc. Series A overvalued?
No, Sagimet Biosciences Inc. Series A is considered undervalued based on the analyst price target (200.1% upside). Sagimet Biosciences Inc. Series A has the following valuation ratios: a P/S ratio of 52.5, a P/B ratio of 4.3. The analyst price target suggests that the stock is undervalued by 200.1%.
Is Sagimet Biosciences Inc. Series A overbought?
No, Sagimet Biosciences Inc. Series A is not overbought. RSI is at 67.6 (neutral zone). The technical indicators show: RSI is at 67.6 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 17.7% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Sagimet Biosciences Inc. Series A earnings report?
Sagimet Biosciences Inc. Series A reports its next earnings on August 12, 2026. The stock currently trades at $8.73. The RSI is at 67.6, so the report can reinforce the current technical trend.
Is Sagimet Biosciences Inc. Series A shorted?
Yes, Sagimet Biosciences Inc. Series A is shorted with 16.1% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Sagimet Biosciences Inc. Series A stock?
No, insiders are not buying Sagimet Biosciences Inc. Series A shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 719,441 $ worth of shares were sold. Across the last 20 reported transactions, the split is 5 purchases and 15 sales, with a net 1,368,379 $ sold. Active sellers include Rozek Elizabeth, Kemble George, Happel David and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Sagimet Biosciences Inc. Series A a good stock?
Based on our total score, Sagimet Biosciences Inc. Series A is rated as a poor stock with a total score of 34 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 10/100, Quality: 11/100, Momentum: 82/100. In addition: analysts see 200.1% upside to the price target; technical signal: Strong Buy. Whether Sagimet Biosciences Inc. Series A is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Sagimet Biosciences Inc. Series A stock?
The outlook for Sagimet Biosciences Inc. Series A based on current data: the average analyst price target is $26.20 (+200.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/12/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Sagimet Biosciences Inc. Series A stock rising?
Sagimet Biosciences Inc. Series A is rising right now. The technical indicators show: the price is 17.7% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 16.1% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Sagimet Biosciences Inc. Series A go?
The average analyst price target for Sagimet Biosciences Inc. Series A is $26.20, which corresponds to a potential gain of 200.1% from the current price of $8.73. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Sagimet Biosciences Inc. Series A fall?
We lack enough history to give a specific floor for Sagimet Biosciences Inc. Series A. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Sagimet Biosciences Inc. Series A do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Sagimet Biosciences Inc. Series A as an investment.
Did Sagimet Biosciences Inc. Series A raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Sagimet Biosciences Inc. Series A. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Sagimet Biosciences Inc. Series A making money or losing money?
We have no current profitability data for Sagimet Biosciences Inc. Series A. See the latest report in the earnings history above.
Can Sagimet Biosciences Inc. Series A go bankrupt?
The bankruptcy risk of Sagimet Biosciences Inc. Series A is rated as low. Altman Z2 (a model for assessing financial distress) is 11.57 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 3% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Sagimet Biosciences Inc. Series A have a lot of debt?
No, Sagimet Biosciences Inc. Series A has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 3%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
